Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Patterns and predictors of change in trauma-focused treatments for war-related posttraumatic stress disorder.

Litz BT, Berke DS, Kline NK, Grimm K, Rusowicz-Orazem L, Resick PA, Foa EB, Wachen JS, McLean CP, Dondanville KA, Borah AM, Roache JD, Young-McCaughan S, Yarvis JS, Mintz J, Peterson AL.

J Consult Clin Psychol. 2019 Nov;87(11):1019-1029. doi: 10.1037/ccp0000426. Epub 2019 Sep 26.

PMID:
31556650
2.

Enhancing Access to Psychiatric Care for Posttraumatic Stress Disorder in Veterans with Mild Traumatic Brain Injury through Integrated Services.

Baig MR, Tapia RN, Meraj A, Pugh JA, Roache JD, Finley EP.

Psychiatr Q. 2019 Aug 24. doi: 10.1007/s11126-019-09668-7. [Epub ahead of print]

PMID:
31446544
3.

Mediation of suicide ideation in prolonged exposure therapy for posttraumatic stress disorder.

Brown LA, Zang Y, Benhamou K, Taylor DJ, Bryan CJ, Yarvis JS, Dondanville KA, Litz BT, Mintz J, Roache JD, Pruiksma KE, Fina BA, Young-McCaughan S, Peterson AL, Foa EB; STRONG STAR Consortium.

Behav Res Ther. 2019 Aug;119:103409. doi: 10.1016/j.brat.2019.103409. Epub 2019 May 23.

PMID:
31176888
4.

Salience Network Disruption in U.S. Army Soldiers With Posttraumatic Stress Disorder.

Abdallah CG, Averill CL, Ramage AE, Averill LA, Goktas S, Nemati S, Krystal JH, Roache JD, Resick PA, Young-McCaughan S, Peterson AL, Fox P; STRONG STAR Consortium.

Chronic Stress (Thousand Oaks). 2019 Jan-Dec;3. doi: 10.1177/2470547019850467. Epub 2019 May 15.

5.

Enhancing Completion of Cognitive Processing Therapy for Posttraumatic Stress Disorder with Quetiapine in Veterans with Mild Traumatic Brain Injury: a Case Series.

Baig MR, Wilson JL, Lemmer JA, Beck RD, Peterson AL, Roache JD.

Psychiatr Q. 2019 Jun;90(2):431-445. doi: 10.1007/s11126-019-09638-z.

PMID:
31054021
6.

Does prolonged exposure increase suicide risk? Results from an active duty military sample.

Brown LA, McLean CP, Zang Y, Zandberg L, Mintz J, Yarvis JS, Litz BT, Peterson AL, Bryan CJ, Fina B, Petersen J, Dondanville KA, Roache JD, Young-McCaughan S, Foa EB; STRONG STAR consortium.

Behav Res Ther. 2019 Jul;118:87-93. doi: 10.1016/j.brat.2019.04.003. Epub 2019 Apr 10.

PMID:
31022593
7.

Reduced Salience and Enhanced Central Executive Connectivity Following PTSD Treatment.

Abdallah CG, Averill CL, Ramage AE, Averill LA, Alkin E, Nemati S, Krystal JH, Roache JD, Resick P, Young-McCaughan S, Peterson AL, Fox P; STRONG STAR Consortium.

Chronic Stress (Thousand Oaks). 2019 Jan-Feb;3. doi: 10.1177/2470547019838971. Epub 2019 Apr 15.

8.

Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial.

Abdallah CG, Roache JD, Averill LA, Young-McCaughan S, Martini B, Gueorguieva R, Amoroso T, Southwick SM, Guthmiller K, López-Roca AL, Lautenschlager K, Mintz J, Litz BT, Williamson DE, Keane TM, Peterson AL, Krystal JH; Consortium to Alleviate PTSD.

Contemp Clin Trials. 2019 Jun;81:11-18. doi: 10.1016/j.cct.2019.04.009. Epub 2019 Apr 15.

PMID:
30999057
9.

Examination of Treatment Effects on Hazardous Drinking Among Service Members With Posttraumatic Stress Disorder.

Dondanville KA, Wachen JS, Hale WJ, Mintz J, Roache JD, Carson C, Litz BT, Yarvis JS, Young-McCaughan S, Peterson AL, Resick PA; STRONG STAR Consortium.

J Trauma Stress. 2019 Apr;32(2):310-316. doi: 10.1002/jts.22393. Epub 2019 Mar 28.

PMID:
30920684
10.

Estimating resource utilization demands in implementing statewide screening, brief intervention, and referral to treatment for alcohol-impaired drivers.

Mathias CW, Moon TJ, Karns-Wright TE, Hill-Kapturczak N, Roache JD, Mullen J, Dougherty DM.

Traffic Inj Prev. 2019;20(1):15-22. doi: 10.1080/15389588.2018.1528500. Epub 2019 Feb 4.

PMID:
30715916
11.

Factor Structure and Psychometric Properties of the Peritraumatic and Posttraumatic Emotions Questionnaires Among Active Duty Military Personnel With Posttraumatic Stress Disorder.

Zang Y, Gay NG, Kaczkurkin AN, McLean CP, Wachen JS, Yarvis JS, Litz BT, Yadin E, Mintz J, Roache JD, Young-McCaughan S, Peterson AL, Foa EB, Resick PA; STRONG STAR Consortium.

J Trauma Stress. 2018 Dec;31(6):826-836. doi: 10.1002/jts.22350. Epub 2018 Dec 12.

PMID:
30548330
12.

The Role of Social Support in Motivating Reductions in Alcohol Use: A Test of Three Models of Social Support in Alcohol-Impaired Drivers.

Moon TJ, Mathias CW, Mullen J, Karns-Wright TE, Hill-Kapturczak N, Roache JD, Dougherty DM.

Alcohol Clin Exp Res. 2019 Jan;43(1):123-134. doi: 10.1111/acer.13911. Epub 2018 Nov 15.

PMID:
30431660
13.

The pattern of symptom change during prolonged exposure therapy and present-centered therapy for PTSD in active duty military personnel.

Brown LA, Clapp JD, Kemp JJ, Yarvis JS, Dondanville KA, Litz BT, Mintz J, Roache JD, Young-McCaughan S, Peterson AL, Foa EB; STRONG STAR Consortium.

Psychol Med. 2019 Sep;49(12):1980-1989. doi: 10.1017/S0033291718002714. Epub 2018 Sep 17.

PMID:
30220261
14.

Processing transdermal alcohol concentration (TAC) data to detect low-level drinking.

Roache JD, Karns-Wright TE, Goros M, Hill-Kapturczak N, Mathias CW, Dougherty DM.

Alcohol. 2018 Sep 1. pii: S0741-8329(18)30110-1. doi: 10.1016/j.alcohol.2018.08.014. [Epub ahead of print]

PMID:
30179708
15.

Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans.

Back SE, Flanagan JC, Jones JL, Augur I, Peterson AL, Young-McCaughan S, Shirley DW, Henschel A, Joseph JE, Litz BT, Hancock AK, Roache JD, Mintz J, Wachen JS, Keane TM, Brady KT; Consortium to Alleviate PTSD.

Contemp Clin Trials. 2018 Oct;73:8-15. doi: 10.1016/j.cct.2018.08.009. Epub 2018 Aug 24.

16.

Design of a clinical effectiveness trial of in-home cognitive processing therapy for combat-related PTSD.

Peterson AL, Resick PA, Mintz J, Young-McCaughan S, McGeary DD, McGeary CA, Velligan DI, Macdonald A, Mata-Galan E, Holliday SL, Dillon KH, Roache JD, Williams Christians I, Moring JC, Bira LM, Nabity PS, Hancock AK, Hale WJ; STRONG STAR Consortium.

Contemp Clin Trials. 2018 Oct;73:27-35. doi: 10.1016/j.cct.2018.08.005. Epub 2018 Aug 23.

PMID:
30144629
17.

Pharmacokinetics of Phosphatidylethanol 16:0/20:4 in Human Blood After Alcohol Intake.

Lopez-Cruzan M, Roache JD, Hill-Kapturczak N, Karns-Wright TE, Dougherty DM, Sanchez JJ, Koek W, Javors MA.

Alcohol Clin Exp Res. 2018 Nov;42(11):2094-2099. doi: 10.1111/acer.13865. Epub 2018 Aug 26.

18.

Intensive prolonged exposure therapy for combat-related posttraumatic stress disorder: Design and methodology of a randomized clinical trial.

Peterson AL, Foa EB, Blount TH, McLean CP, Shah DV, Young-McCaughan S, Litz BT, Schobitz RP, Castillo DT, Rentz TO, Yarvis JS, Dondanville KA, Fina BA, Hall-Clark BN, Brown LA, DeBeer BR, Jacoby VM, Hancock AK, Williamson DE, Evans WR, Synett S, Straud C, Hansen HR, Meyer EC, Javors MA, Sharrieff AM, Lara-Ruiz J, Koch LM, Roache JD, Mintz J, Keane TM; Consortium to Alleviate PTSD.

Contemp Clin Trials. 2018 Sep;72:126-136. doi: 10.1016/j.cct.2018.07.016. Epub 2018 Jul 25.

PMID:
30055335
19.

The correspondence between transdermal alcohol monitoring and daily self-reported alcohol consumption.

Karns-Wright TE, Dougherty DM, Hill-Kapturczak N, Mathias CW, Roache JD.

Addict Behav. 2018 Oct;85:147-152. doi: 10.1016/j.addbeh.2018.06.006. Epub 2018 Jun 11.

20.

Impact of cognitive behavioral therapy for insomnia disorder on sleep and comorbid symptoms in military personnel: a randomized clinical trial.

Taylor DJ, Peterson AL, Pruiksma KE, Hale WJ, Young-McCaughan S, Wilkerson A, Nicholson K, Litz BT, Dondanville KA, Roache JD, Borah EV, Brundige A, Mintz J; STRONG STAR Consortium.

Sleep. 2018 Jun 1;41(6). doi: 10.1093/sleep/zsy069.

PMID:
29618098
21.

Differences in the Synthesis and Elimination of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 After Acute Doses of Alcohol.

Hill-Kapturczak N, Dougherty DM, Roache JD, Karns-Wright TE, Javors MA.

Alcohol Clin Exp Res. 2018 May;42(5):851-860. doi: 10.1111/acer.13620. Epub 2018 Mar 30.

22.

Translating transdermal alcohol monitoring procedures for contingency management among adults recently arrested for DWI.

Mathias CW, Hill-Kapturczak N, Karns-Wright TE, Mullen J, Roache JD, Fell JC, Dougherty DM.

Addict Behav. 2018 Aug;83:56-63. doi: 10.1016/j.addbeh.2018.01.033. Epub 2018 Jan 31.

23.

Moving effective treatment for posttraumatic stress disorder to primary care: A randomized controlled trial with active duty military.

Cigrang JA, Rauch SA, Mintz J, Brundige AR, Mitchell JA, Najera E, Litz BT, Young-McCaughan S, Roache JD, Hembree EA, Goodie JL, Sonnek SM, Peterson AL; STRONG STAR Consortium.

Fam Syst Health. 2017 Dec;35(4):450-462. doi: 10.1037/fsh0000315.

PMID:
29283612
24.

Caffeine Use in Military Personnel With PTSD: Prevalence and Impact on Sleep.

McLean CP, Zandberg L, Roache JD, Fitzgerald H, Pruiksma KE, Taylor DJ, Dondanville KA, Litz BT, Mintz J, Young-McCaughan S, Yarvis JS, Peterson AL, Foa EB; STRONG STAR Consortium.

Behav Sleep Med. 2017 Jun 13:1-11. doi: 10.1080/15402002.2017.1326920. [Epub ahead of print]

PMID:
28609150
25.

Effect of Group vs Individual Cognitive Processing Therapy in Active-Duty Military Seeking Treatment for Posttraumatic Stress Disorder: A Randomized Clinical Trial.

Resick PA, Wachen JS, Dondanville KA, Pruiksma KE, Yarvis JS, Peterson AL, Mintz J; and the STRONG STAR Consortium, Borah EV, Brundige A, Hembree EA, Litz BT, Roache JD, Young-McCaughan S.

JAMA Psychiatry. 2017 Jan 1;74(1):28-36. doi: 10.1001/jamapsychiatry.2016.2729. Erratum in: JAMA Psychiatry. 2017 Jun 1;74(6):655.

PMID:
27893032
26.

Behavioral Impulsivity Does Not Predict Naturalistic Alcohol Consumption or Treatment Outcomes.

Mullen J, Mathias CW, Karns TE, Liang Y, Hill-Kapturczak N, Roache JD, Lamb RJ, Dougherty DM.

Addict Disord Their Treat. 2016 Sep;15(3):120-128.

27.

Time Delays in Transdermal Alcohol Concentrations Relative to Breath Alcohol Concentrations.

Karns-Wright TE, Roache JD, Hill-Kapturczak N, Liang Y, Mullen J, Dougherty DM.

Alcohol Alcohol. 2017 Jan;52(1):35-41. doi: 10.1093/alcalc/agw058. Epub 2016 Aug 13.

28.

Characterization of the Pharmacokinetics of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 in Human Whole Blood After Alcohol Consumption in a Clinical Laboratory Study.

Javors MA, Hill-Kapturczak N, Roache JD, Karns-Wright TE, Dougherty DM.

Alcohol Clin Exp Res. 2016 Jun;40(6):1228-34. doi: 10.1111/acer.13062. Epub 2016 Apr 30.

29.

Qualitative examination of cognitive change during PTSD treatment for active duty service members.

Dondanville KA, Blankenship AE, Molino A, Resick PA, Wachen JS, Mintz J, Yarvis JS, Litz BT, Borah EV, Roache JD, Young-McCaughan S, Hembree EA, Peterson AL; STRONG STAR Consortium.

Behav Res Ther. 2016 Apr;79:1-6. doi: 10.1016/j.brat.2016.01.003. Epub 2016 Feb 4.

PMID:
26874683
30.

The Potential Clinical Utility of Transdermal Alcohol Monitoring Data to Estimate the Number of Alcoholic Drinks Consumed.

Dougherty DM, Hill-Kapturczak N, Liang Y, Karns TE, Lake SL, Cates SE, Roache JD.

Addict Disord Their Treat. 2015 Sep;14(3):124-130.

31.

Using Transdermal Alcohol Monitoring to Detect Low-Level Drinking.

Roache JD, Karns TE, Hill-Kapturczak N, Mullen J, Liang Y, Lamb RJ, Dougherty DM.

Alcohol Clin Exp Res. 2015 Jul;39(7):1120-7. doi: 10.1111/acer.12750. Epub 2015 May 18.

32.

A randomized clinical trial of group cognitive processing therapy compared with group present-centered therapy for PTSD among active duty military personnel.

Resick PA, Wachen JS, Mintz J, Young-McCaughan S, Roache JD, Borah AM, Borah EV, Dondanville KA, Hembree EA, Litz BT, Peterson AL.

J Consult Clin Psychol. 2015 Dec;83(6):1058-1068. doi: 10.1037/ccp0000016. Epub 2015 May 4.

PMID:
25939018
33.

Using contingency management procedures to reduce at-risk drinking in heavy drinkers.

Dougherty DM, Lake SL, Hill-Kapturczak N, Liang Y, Karns TE, Mullen J, Roache JD.

Alcohol Clin Exp Res. 2015 Apr;39(4):743-51. doi: 10.1111/acer.12687.

34.

Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.

Anderson AL, Li SH, Markova D, Holmes TH, Chiang N, Kahn R, Campbell J, Dickerson DL, Galloway GP, Haning W, Roache JD, Stock C, Elkashef AM.

Drug Alcohol Depend. 2015 May 1;150:170-4. doi: 10.1016/j.drugalcdep.2015.01.036. Epub 2015 Feb 7.

35.

Assessing the Validity of Participant-Derived Compared to Staff-Derived Values to Compute a Binge Score.

Lake SL, Hill-Kapturczak N, Liang Y, Roache JD, Mullen J, Karns TE, Dougherty DM.

Alcohol Alcohol. 2015 Jul;50(4):413-9. doi: 10.1093/alcalc/agv018. Epub 2015 Mar 13.

36.

Effects of tryptophan depletion and a simulated alcohol binge on impulsivity.

Dougherty DM, Mullen J, Hill-Kapturczak N, Liang Y, Karns TE, Lake SL, Mathias CW, Roache JD.

Exp Clin Psychopharmacol. 2015 Apr;23(2):109-21. doi: 10.1037/a0038943. Epub 2015 Mar 2.

37.

Transdermal alcohol concentration data collected during a contingency management program to reduce at-risk drinking.

Dougherty DM, Karns TE, Mullen J, Liang Y, Lake SL, Roache JD, Hill-Kapturczak N.

Drug Alcohol Depend. 2015 Mar 1;148:77-84. doi: 10.1016/j.drugalcdep.2014.12.021. Epub 2014 Dec 31. Erratum in: Drug Alcohol Depend. ;149:304.

38.

Do variable rates of alcohol drinking alter the ability to use transdermal alcohol monitors to estimate peak breath alcohol and total number of drinks?

Hill-Kapturczak N, Lake SL, Roache JD, Cates SE, Liang Y, Dougherty DM.

Alcohol Clin Exp Res. 2014 Oct;38(10):2517-22. doi: 10.1111/acer.12528. Epub 2014 Oct 21.

39.

Use of continuous transdermal alcohol monitoring during a contingency management procedure to reduce excessive alcohol use.

Dougherty DM, Hill-Kapturczak N, Liang Y, Karns TE, Cates SE, Lake SL, Mullen J, Roache JD.

Drug Alcohol Depend. 2014 Sep 1;142:301-6. doi: 10.1016/j.drugalcdep.2014.06.039. Epub 2014 Jul 11.

40.

Accounting for sex-related differences in the estimation of breath alcohol concentrations using transdermal alcohol monitoring.

Hill-Kapturczak N, Roache JD, Liang Y, Karns TE, Cates SE, Dougherty DM.

Psychopharmacology (Berl). 2015 Jan;232(1):115-23. doi: 10.1007/s00213-014-3644-9. Epub 2014 Jun 13.

41.

A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.

Somoza EC, Winship D, Gorodetzky CW, Lewis D, Ciraulo DA, Galloway GP, Segal SD, Sheehan M, Roache JD, Bickel WK, Jasinski D, Watson DW, Miller SR, Somoza P, Winhusen T.

JAMA Psychiatry. 2013 Jun;70(6):630-7. doi: 10.1001/jamapsychiatry.2013.872.

PMID:
23575810
42.

The need for expanded monitoring of adverse events in behavioral health clinical trials.

Peterson AL, Roache JD, Raj J, Young-McCaughan S; STRONG STAR Consortium.

Contemp Clin Trials. 2013 Jan;34(1):152-4. doi: 10.1016/j.cct.2012.10.009. Epub 2012 Oct 29. Review.

PMID:
23117077
43.

Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking.

Johnson BA, Roache JD, Ait-Daoud N, Gunderson EW, Haughey HM, Wang XQ, Liu L.

Addict Biol. 2013 May;18(3):405-16. doi: 10.1111/j.1369-1600.2012.00499.x. Epub 2012 Oct 8.

44.

Commentary on comparison of alcoholism subtypes as moderators of the response to sertraline treatment.

Roache JD.

Alcohol Clin Exp Res. 2012 Apr;36(4):561-3. doi: 10.1111/j.1530-0277.2012.01781.x. Epub 2012 Mar 20. No abstract available.

PMID:
22432698
45.

Preliminary Evidence for cue-induced Alcohol Craving Modulated by Serotonin Transporter Gene Polymorphism rs1042173.

Ait-Daoud N, Seneviratne C, Smith JB, Roache JD, Dawes MA, Liu L, Wang XQ, Johnson BA.

Front Psychiatry. 2012 Feb 16;3:6. doi: 10.3389/fpsyt.2012.00006. eCollection 2012.

46.

A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram.

Roache JD, Kahn R, Newton TF, Wallace CL, Murff WL, De La Garza R 2nd, Rivera O, Anderson A, Mojsiak J, Elkashef A.

Drug Alcohol Depend. 2011 Dec 1;119(1-2):37-45. doi: 10.1016/j.drugalcdep.2011.05.015. Epub 2011 Jun 21.

47.

Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.

Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD.

Am J Psychiatry. 2011 Mar;168(3):265-75. doi: 10.1176/appi.ajp.2010.10050755. Epub 2011 Jan 19. Erratum in: Am J Psychiatry. 2011 Jul;168(7):756.

48.

Drinking histories in alcohol-use-disordered youth: preliminary findings on relationships to platelet serotonin transporter expression with genotypes of the serotonin transporter.

Dawes MA, Roache JD, Javors MA, Bergeson SE, Richard DM, Mathias CW, Ait-Daoud N, Dougherty DM, Johnson BA.

J Stud Alcohol Drugs. 2009 Nov;70(6):899-907.

49.

Modafinil for the treatment of cocaine dependence.

Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, Smith EV, Kahn R, Chiang N, Vocci F, Ciraulo D, Dackis C, Roache JD, Salloum IM, Somoza E, Urschel HC 3rd, Elkashef AM.

Drug Alcohol Depend. 2009 Sep 1;104(1-2):133-9. doi: 10.1016/j.drugalcdep.2009.04.015. Epub 2009 Jun 26.

50.

Can serotonin transporter genotype predict craving in alcoholism?

Ait-Daoud N, Roache JD, Dawes MA, Liu L, Wang XQ, Javors MA, Seneviratne C, Johnson BA.

Alcohol Clin Exp Res. 2009 Aug;33(8):1329-35. doi: 10.1111/j.1530-0277.2009.00962.x. Epub 2009 May 4.

Supplemental Content

Loading ...
Support Center